60,398 Shares in Heron Therapeutics Inc (HRTX) Acquired by Alps Advisors Inc.
Alps Advisors Inc. bought a new position in Heron Therapeutics Inc (NASDAQ:HRTX) during the 4th quarter, HoldingsChannel reports. The fund bought 60,398 shares of the biotechnology company’s stock, valued at approximately $1,093,000.
A number of other hedge funds have also recently modified their holdings of HRTX. Perceptive Advisors LLC acquired a new position in Heron Therapeutics in the 3rd quarter worth about $5,329,000. Vanguard Group Inc. increased its position in Heron Therapeutics by 11.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock worth $29,036,000 after purchasing an additional 221,362 shares during the last quarter. Rubric Capital Management LP increased its position in Heron Therapeutics by 11.8% in the 3rd quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock worth $30,685,000 after purchasing an additional 200,000 shares during the last quarter. Chartwell Investment Partners LLC acquired a new position in Heron Therapeutics in the 3rd quarter worth about $2,340,000. Finally, Janus Henderson Group PLC increased its position in Heron Therapeutics by 2.2% in the 3rd quarter. Janus Henderson Group PLC now owns 5,767,495 shares of the biotechnology company’s stock worth $93,145,000 after purchasing an additional 126,039 shares during the last quarter. 98.37% of the stock is currently owned by institutional investors.
Several research analysts have weighed in on the company. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Zacks Investment Research raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Oppenheimer reaffirmed a “buy” rating and issued a $27.00 target price on shares of Heron Therapeutics in a research report on Friday, November 10th. Finally, Cantor Fitzgerald set a $31.00 target price on Heron Therapeutics and gave the stock a “buy” rating in a research report on Friday, January 5th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $28.82.
Shares of Heron Therapeutics Inc (NASDAQ:HRTX) opened at $20.50 on Friday. The stock has a market capitalization of $1,130.00, a PE ratio of -5.41 and a beta of 1.87. Heron Therapeutics Inc has a 52 week low of $12.70 and a 52 week high of $24.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12.
COPYRIGHT VIOLATION NOTICE: This report was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://theolympiareport.com/2018/02/11/60398-shares-in-heron-therapeutics-inc-hrtx-acquired-by-alps-advisors-inc.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.